<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595877</url>
  </required_header>
  <id_info>
    <org_study_id>1093-10</org_study_id>
    <nct_id>NCT04595877</nct_id>
  </id_info>
  <brief_title>Double-blind, Randomized Controlled Study to Assess the Analgesic Effect of 2 g of Magnesium Dipyrone (Metamizol) and Changes in Plasma Beta-endorphin Immunoreactivity Values in Patients Undergoing Elective Inguinal Herniorrhaphy Under Epidural Anesthesia.</brief_title>
  <official_title>Double-blind, Randomized Controlled Study to Assess the Analgesic Effect of a Single Intravenous Dose of 2 g of Magnesium Dipyrone (Metamizol) and Changes in Plasma Beta-endorphin Immunoreactivity (Beta-EPIr) Values in Patients Undergoing Elective Inguinal Herniorrhaphy (Bassini Operation) Under Epidural Anesthesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonio Martín Duce</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alcala</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized controlled study is designed to assess the analgesic effect of a&#xD;
      single intravenous dose of 2 g of magnesium dipyrone (metamizol) and whether the&#xD;
      administration of the active drug will be associated with changes in plasma beta-endorphin&#xD;
      immunoreactivity values in patients undergoing elective inguinal herniorrhaphy (Bassini&#xD;
      operation) under epidural anesthesia. Participants, care givers, and those assessing the&#xD;
      outcomes will be blinded to group assignment. Participants will be randomized to receive&#xD;
      dipyrone or a placebo. The active drug or placebo will be administered as an intravenous&#xD;
      infusion over 10 min. Pain will be evaluated by the patient according to a 100-mm visual&#xD;
      analogue scale. Assessments will be carried out the day before surgery, immediately after&#xD;
      operation, at the time of drug administration, and 60 and 180 min after treatment. At the&#xD;
      same time as pain will be evaluated, blood samples will be drawn for plasma beta-endorphin&#xD;
      immunoreactivity measurement (immunoradiometric assay).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessors and data analysts will be kept blinded to the allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic efficacy-Pain relief</measure>
    <time_frame>30 seconds</time_frame>
    <description>Visual Analogue Scale score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-endorphins levels.</measure>
    <time_frame>1 minute</time_frame>
    <description>Beta-endorphin immunoreactivity levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <condition>Beta-endorphin</condition>
  <condition>Dipyrone</condition>
  <condition>Hernia Surgery</condition>
  <arm_group>
    <arm_group_label>Dipyrone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyrone administration</intervention_name>
    <description>Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.</description>
    <arm_group_label>Dipyrone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pain assessment</intervention_name>
    <description>Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 &quot;no pain&quot; to point 10 &quot;unbearable pain&quot;).</description>
    <arm_group_label>Dipyrone group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>beta-endorphin immunoreactivity</intervention_name>
    <description>Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.</description>
    <arm_group_label>Dipyrone group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo administration</intervention_name>
    <description>Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years, elective surgery, routine laboratory tests (blood cell count, biochemical&#xD;
             profile, urinalysis), chest radiography, twelve-lead electrocardiography, body mass&#xD;
             index (BMI), blood pressure, pulse rate normal or abnormal values without clinical&#xD;
             relevance and a mental status sufficient to be able to complete efficacy tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had taken other analgesics or anti-inflammatory drugs 24 h before&#xD;
             surgery, as those with known hypersensitivity to the drug or with any other disorder&#xD;
             contradicting the administration of dipyrone. Patients with hypersensitivity to&#xD;
             non-steroidal anti-inflammatory agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nursing and Physiotherapy Department</name>
      <address>
        <city>Madrid</city>
        <state>Alcalá De Henares</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alcala</investigator_affiliation>
    <investigator_full_name>Antonio Martín Duce</investigator_full_name>
    <investigator_title>Dr. Antonio Martin Duce</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>Endorphins</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

